Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer

Inclusion Criteria

• •female patients aged greater than or equal to 18 years and less than or equal to 75 years, meet one of the following:
• •1. previous oophorectomy, or age ≥ 60 years;
• •2. age \< 60 years, natural postmenopausal status (defined as at least 12 consecutive months of spontaneous cessation of regular menstruation, and no other pathological or physiological causes), E2 and FSH in postmenopausal levels;
• •3. premenopausal or perimenopausal female patients, must be willing to receive LHRH agonist therapy during the study;
• •all patients were confirmed by histopathology as estrogen receptor (ER) positive (\> 10%), HER2 receptor negative.Follow the 2018 version of ASCO-CAP HER2-negative interpretation guideline criteria;
• •tumor stage II-III meeting the AJCC 8th version criteria, patients who have previously received 2 cycles of TE regimen chemotherapy, with disease evaluation of SD or PD;
• •KPS score ≥ 70 points;
• •organ function level must meet the following requirements:
• •1. bone marrow function ANC ≥ 1.5 × 109/L (14 without growth factors); PLT ≥ 100 × 109/L (7 without corrective treatment); Hb ≥ 100 g/L (7) without corrective treatment;
• •2. liver and kidney function TBIL ≤ 1.5 × ULN; ALT and AST ≤ 3 × ULN; BUN and Cr ≤ 1.5 × ULN and creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula);
• •able to undergo needle biopsy;
• •voluntarily join this study, sign informed consent, have good compliance and are willing to cooperate with follow-up